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Abstract
Due to physical hindrance and time spent in hospital, a cancer diagnosis can lead to distur-
bance of personally important goals. Goal disturbance in cancer patients has been related
to poorer psychological well-being. However, the relation with physiological measures is
yet unknown. The purpose of the current study is to examine the impact of goal disturbance
on cortisol as a measure of response to stress over time, and a possibly moderating role
of a DNA genotype associated with HPA-axis functioning, Catechol-O-Methyl transferase
(COMT). We examined the predictive value of goal disturbance on Cortisol Awakening
Response (CAR) and Diurnal Cortisol Slope (DCS) over two periods: 1–7 and 7–18 months
post-diagnosis, and the moderating role of COMT during these periods. Hierarchical regres-
sion analyses showed that goal disturbance 7 months post-diagnosis significantly predicted
a steeper CAR a year later. During that period, the slow COMT variant moderated the rela-
tion, in that patients reporting high goal disturbance and had the Met/Met variant, had a
more flattened CAR. No other significant effects were found. As steeper CARs have been
related to adverse health outcomes, and COMT genotype may modify this risk, these results
indicate that goal disturbance and genotype may be important factors to consider in main-
taining better psychological and physical health in the already vulnerable population of can-
cer patients.
Introduction
The successful pursuit of personal goals is important for maintaining well-being [1], as goals
provide a sense of purpose in life and motivate daily activities [2,3]. The diagnosis of a poten-
tially life-threatening disease as cancer may lead to goals being more difficult to achieve due to
the physical implications of the illness and/or its treatment [4,5]. Evidence suggests that this
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disturbance of personal goals leads to decreased levels of psychological well-being in cancer
patients [4,6,7].
A less researched question concerns the relationship between goal disturbance after cancer
and physiological measures. In one study in healthy people, it was found that hindrances in goal
attainment led to increased levels of cortisol [8], providing a first indication that goal disturbance
can be considered a stressor impacting physiological outcomes. Cortisol is a hormone which
secretion is regulated by the hypothalamo-pituitary-adrenal (HPA) axis and can be used to mea-
sure the response to stress. The HPA-axis is a pathway through which psychological factors can
influence biological processes [9], and stress has been found to influence cortisol production
[10,11]. Indeed, worries and daily stressors, like goal disturbance after cancer diagnosis, have
been linked to steeper Cortisol Awakening Responses (CAR, increase in cortisol between awak-
ening and 30–45 minutes later) [12–17] and flattened Diurnal Cortisol Slopes (DCS, decrease in
cortisol between 30–45 minutes after awakening and bedtime) [18–22], which have been related
to lower levels of psychological as well as psychical well-being [20,23–26]. In the current study,
we will investigate the longitudinal impact of goal disturbance due to cancer on cortisol levels.
Catechol-O-Methyl transferase (COMT, EC 2.1.1.6) is an enzyme involved in the degradation
of catecholamines. It is encoded by the COMT gene (chromosome 22 band q11.2) that displays
several allelic variants of which the functional single nucleotide polymorphismVal158Met is most
studied [27,28]. This functional polymorphism in the COMT gene is the result of a G to A muta-
tion that translates into a valine (val) to methionine (met) substitution at codon 158. It has been
shown to account for a four-fold decrease in enzyme activity in degrading cortical dopamine (cat-
echolamines) [29]. Catecholamines modulate the endocrine stress reactivity through its impact
on those parts of the brain that regulate the functioning of the HPA-axis [30]. Therefore, the
genetic differences in the dopaminergic system (as modified by e.g. COMT) can lead to differ-
ences in the reactivity of the HPA-axis. As the HPA-axis regulates cortisol secretion, the COMT
variants may have influence on cortisol reactivity [31,32]. In the general population, three com-
mon variants, Val/Val, Val/Met, and Met/Met, have been identified [33]. The low-activity Met/
Met genotype has been associated with reduced COMT enzyme activity in the brain [29,32]. Low
enzyme activity leads to an impaired endocrine response to stress [28]. It could thus be that,
when experiencing stress, Met/Met carriers would show a more flattened CAR and DCS, as they
are less able to degrade catecholamines, leading to lower HPA-axis reactivity and an impaired
ability to regulate or degrade cortisol levels. Therefore, it could be hypothesised that cancer
patients who experience stress through goal disturbance and have the Met/Met genotype, would
show more flattened CAR and DCS than cancer patients with a Val/Val or Val/Met genotype. In
the present study, we investigated to what extent the COMT Val158Met polymorphism moder-
ates the relation between goal disturbance and cortisol levels.
The present study is the first to undertake a longitudinal analysis of goal disturbance and corti-
sol levels in cancer patients, and the moderating role of COMT.We hypothesise that 1) higher
goal disturbance within a month after diagnosis predicts a steeper CAR and flattened DCS six
months later, and that higher goal disturbance seven months post-diagnosis predicts a steeper
CAR and flattened DCS one year later. Additionally, we expect that 2) COMT genotype moder-
ates the relation between goal disturbance and cortisol levels, in that the Met/Met variant would
lead to a more flattened CAR and DCS after goal disturbance than Val/Val or Val/Met genotypes.
Methods
Sample
Recently diagnosed colorectal cancer patients were recruited between September 2011 and
March 2013 in four different hospitals across the Netherlands. Patients had to be over 18 years
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old to be eligible. Those who had a cognitive impairment or psychiatric disorder, were unable
to understand Dutch, or had drug or alcohol problems, were excluded from participation. The
study included three assessments: within a month, 7 and 18 months post-diagnosis. At all three
assessments, patients were interviewed by the same interviewer at a place of their choice (usu-
ally their homes). The study was approved by the Medical Ethical Committee of the University
Medical Center in Groningen, the Netherlands, and all participants provided written informed
consent. This consent procedure was approved by the ethical committee.
Measures
Demographic and clinical variables. At the first assessment, patients reported their age,
gender, marital status and highest level of educational attainment. From the Netherlands Can-
cer Registry (NCR), we obtained information on prognosis (using the Tumour Node Metastasis
(TNM) Classification of Malignant Tumours, ranging from Stage I, local tumour without
metastases, to Stage IV, invasive tumour with metastases), presence of a stoma (yes/no), site of
the tumour (colon or rectum), and whether patients underwent chemo—and/or radiotherapy
in addition to surgery during the course of the study (yes/no).
Goal disturbance. In a recent review on life goals in cancer patients, goal disturbance was
identified as the most studied aspect of the goal construct [34]. However, the review also
showed that there is no ‘golden standard’ or validated scale that was used most often. A com-
mon way to assess dimensions or structural aspects of personal goals, such as goal disturbance,
is to first assess personal goals, and then let respondents appraise these goals on structural
aspects (e.g. goal importance, effort, or disturbance) [2,3,35]. Indeed, most studies assess goal
disturbance by asking respondents to rate their goals (either freely elicited or from a pre-
defined list of goals) on goal disturbance or goal hindrance (e.g. [4,36–39]). The present study
therefore assesses goal disturbance by first asking patients to freely list three to ten personal
goals, and then rate for each goal the extent to which cancer hindered the achievement of that
goal on a 10-point scale (ranging from 1 = not at all, 10 = completely). Mean goal disturbance
scores from all goals were then calculated for each assessment.
COMT genotype and cortisol. During the first assessment (i.e. within one month post-
diagnosis), COMT genotype was assessed in salivary DNA samples obtained with DNA Collec-
tion kits (Oragene by Genotek). The interviewer took a kit to the interview and the patient was
asked to fill the cup with saliva. The interviewer then mailed the cup to the researchers at the
University Medical Center Groningen, who took it to the Department of Laboratory Medicine.
Mailing of the DNA samples is not known to affect their quality [40].
Seven and 18 months post-diagnosis, saliva was collected to assess cortisol. Collection kits (con-
taining salivettes, see below) were mailed to the participants prior to these assessments. Patients
collected three samples per day for two consecutive days at both assessments: immediately upon
waking, 30 minutes later, and at bedtime. All samples were numbered consecutively by time
and day by the researchers before they were sent. Patients were telephoned by a member of the
research team to inform them that they would receive a saliva collection kit with a detailed instruc-
tion sheet. During the call, patients were instructed how to collect the samples and asked to do so
in the week before the interviewer would come to visit them. Patients were reminded of the impor-
tance of compliance with the instructions and told to store the collected samples in the refrigerator.
After the interviewers had conducted the interviews, they collected the samples and mailed the
collection kits to the Department of Laboratory Medicine at the University Medical Center Gro-
ningen. Those patients who did not complete saliva collection prior to the interview, mailed the kit
themselves in a pre-paid envelope. Mailing of samples to the laboratory has not been known to
affect the quality of the samples [41], and this procedure is commonly used in similar studies [9].
Goal Disturbance and Cortisol
PLOS ONE | DOI:10.1371/journal.pone.0135708 August 27, 2015 3 / 14
Patients had to place a synthetic cotton roll in their mouth (Sarstedt Salivettes), chew until it
was saturated with saliva and return the cotton in a vial. They were asked to collect the samples
on weekdays (due to the differences in CAR between weekdays and weekends [13]), and not to
brush their teeth or eat within 30 minutes before collection to avoid contamination of the sam-
ple with blood or food. Patients were instructed to write down the exact time of collection of
each saliva sample, as well as the exact times of awakening and bedtime, on a registration form
provided by the researchers. They were also asked to indicate whether they had diabetes or not,
as this may influence cortisol levels [42]. Cortisol was analysed by isotope dilution mass spec-
trometry, essentially as described in Jones et al. [43]. Intra-assay CV were 8.6%, 2.1%, and
2.1%, inter-assay CV were 9.6%, 5.2%, and 4.5% at respectively 0.48, 2.7, and 11 nmol/L.
Data analysis
Cortisol values were not normally distributed, and therefore we used a logarithmic transforma-
tion to normalise the data [9]. CAR was examined by calculating the difference between the
sample collected immediately upon awakening and 30–45 minutes later [16,44–46]. To
increase the reliability and reduce situational influences, CAR scores of the two consecutive
days were averaged to arrive at one CAR per assessment [47]. We calculated the DCS by sub-
tracting the bedtime sample from the sample collected 30–45 minutes after awakening and
divided this by the number of hours passed [9,16,44]. The DCS of the two consecutive days
were averaged to form the DCS per assessment.
A decrease in CAR, and therefore a negative CAR value, could occur either due to a natural
reaction, or due to non-adherence with respect to time of sample collection. To control for pos-
sible non-adherence or other unknown variables which can affect CAR, we followed Almela
et al.’s approach (based on [48]) by replicating analyses for all patients who showed a positive
CAR (and therefore the expected increase in cortisol) on both days per assessments (the 2-day
CAR group), and those who did so at only one or none of the days (the 1–0 or 0–0 day CAR
group).
Several factors have been suggested to influence cortisol levels [49,50], and should therefore
be taken into account. Among the most commonly studied factors are age and gender, partici-
pant adherence, weekdays vs. weekend collections, sleep duration, and time of waking. Partici-
pant adherence, weekdays vs. weekend collections, sleep duration and time of waking were
controlled for when preparing the sample. Age and gender were controlled for in the analyses.
In addition, HPA-axis functioning can be affected by psychiatric disorders [51]. In the current
study however, presence of a psychiatric disorder was an exclusion criteria. This factor will
therefore not influence the study’s findings.
First, we used descriptive statistics to investigate the characteristics of the sample. Hierarchi-
cal regression analyses were used to assess the predictive value of goal disturbance on CAR and
DCS from within one month to 7 months post-diagnosis, and from 7 months post-diagnosis to
18 months post-diagnosis. Since our primary interest was the relation between goal disturbance
and cortisol levels, we tested their correlations with demographic and clinical variables, to
investigate whether we should control for any of these variables in the regression analyses. No
significant correlations were found between cortisol levels, age, gender, stage of cancer, and
whether they received chemo- and or radiotherapy during the course of the study. However, as
age and gender have been suggested as factors that could influence cortisol levels, these factors
were entered in step one of the analyses. Goal disturbance was entered in step two. As COMT
is a categorical variable with three categories, it was recoded using two dummy variables (Val/
Val 0 = no, 1 = yes and Met/Met 0 = no, 1 = yes, with the intermediate active Val/Met type as
reference value) and entered in step three of the regression analyses [52]. To investigate and
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interpret a possible interaction effect, we first centered the predictor goal disturbance by sub-
tracting the mean from each data point, so that the new centered variables have zero as the
mean. We then calculated the two interaction variables using the two dummy variables and
entered these in step four of the regression analysis. We used an alpha of 0.05 to test for signifi-
cance (2-sided). Statistical Package for Social Sciences (IBM SPSS) version 22.0 for Windows
was used for the statistical analysis.
Results
Sample characteristics
In total, 497 patients were offered information concerning the study. Of these patients, 117
refused this information. Of the 380 patients who received the information, 228 agreed to par-
ticipate (response rate: 45.9%), 219 completed the first assessment, and 186 patients completed
all three assessments (drop-out: 15.1%). All patients were asked to collect saliva, for DNA isola-
tion for COMT analysis and for cortisol analysis, but of the 186 patients who completed all
assessments, ten patients did not provide consent for COMT, cortisol, or both, at the start of
the study. Eighteen patients were unable to collect cortisol 7 months post-diagnosis and fifteen
18 months post-diagnosis, mostly due to the severity of their illness. Of the 143 patients who
collected cortisol, 114 returned more than 50% of their samples, which were of sufficient qual-
ity to be analysed. Fifteen patients were then excluded because the time registration was filled
out incompletely (less than 50%) or was not returned with the samples, and one further patient
was excluded as no cortisol was present in the returned samples, leaving suitable samples of 98
patients.
Following Karlamangla et al. [53], we then excluded respondents with extreme waking day
lengths (> 20h) (n = 1) and extreme waking times (before 04:00 AM and after 11:00 AM)
(n = 2). Additionally, given the importance of time elapsed since awakening on cortisol awak-
ening response [54], we excluded participants who, at any day, failed to collect the first saliva
sample within 30 minutes after awakening and the second saliva sample within 30 minutes
after the first assessment with a margin of plus or minus 15 minutes (n = 10). Patients who
failed to register time of awakening were also excluded because we could not be sure whether
the saliva sample was collected within 30–45 minutes after awakening (n = 13). We therefore
could analyse cortisol samples of 72 patients (see Fig 1 for the complete flowchart).
Table 1 presents the demographic characteristics. The 72 patients were, on average, 65.2 years
old, mostly male (58.3%), with a partner (83.3%), and completed at least high school (63.9%).
Most patients were diagnosed with either Stage II or III colorectal cancer, did not have a stoma
and had a tumour located in the colon. Almost half of patients (47.2%) received chemotherapy
or radiotherapy in addition to surgery during the study. For two patients, COMT genotype could
not be determined. Of the remaining patients, 16 (22.2%) had the Val/Val genotype, 32 (44.4%)
the Val/Met genotype and 22 (30.6%) the Met/Met genotype. Three patients reported to have
diabetes. The demographic characteristics did not differ significantly from the original sample of
186 patients, except with respect to presence of a stoma: patients in the current sample less often
had a stoma compared to those in the original sample. Age, gender and stage of illness also did
not differ from the 219 patients who completed the first assessment.
Table 2 presents data on goal disturbance, mean levels of cortisol, and CAR and DCS over
time. Scores on goal disturbance ranged from 1–10. The sample of 72 patients did not differ
significantly on levels of goal disturbance from the 114 patients who dropped out or were
excluded at all three assessments. At the second assessment, 40 patients (54.1%) showed a posi-
tive CAR on both days, while at the third assessment, 30 patients (40.5%) showed a positive
CAR on both days. For DCS, 3 samples were excluded as they showed an increase of more than
Goal Disturbance and Cortisol
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10 nmol/L, as this may reflect that the second sample was not captured at the cortisol peak
[44]. There were no significant differences in CAR and DCS over time. At both assessments,
there were no significant COMT group differences in mean levels of cortisol and CAR. The
only significant group differences however, were with respect to the DCS at the second assess-
ment, where patients with the Met/Met variant showed the most flattened DCS compared to
the other two variants (p<.001).
Fig 1. Flowchart of patients who provided useful samples.
doi:10.1371/journal.pone.0135708.g001
Goal Disturbance and Cortisol
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Prediction of goal disturbance on cortisol levels (hypothesis 1)
Tables 3 and 4 present the results of the hierarchical regression analyses on the predictive value
of goal disturbance on cortisol at the second and third assessment, respectively. Goal distur-
bance within a month following cancer diagnosis was insignificantly related to either CAR or
DCS six months later (see Table 3). Using only the group who showed an increase in CAR on
both days of the assessment (the 2-day CAR group) to predict CAR 7 months post-diagnosis
did not show any significant results (results not shown). In line with our hypothesis, a high
level of goal disturbance seven months post-diagnosis was significantly related to steeper CAR
one year later (see Table 4). Using only the 2-day CAR group to predict CAR 18 months post-
diagnosis did not show any significant results (results not shown).
Moderating role of COMT of the relation between goal disturbance and
cortisol levels (hypothesis 2)
Interaction analyses were performed to investigate the moderating role of COMT between goal
disturbance and cortisol levels (see Tables 3 and 4). The main effect of having the Val/Val
genotype, as well as having the Met/Met genotype, on cortisol was tested. The Val/Met geno-
type was used as the reference category. No significant interactions were found during the
period 1–7 months post-diagnosis for either CAR or DCS. During the period 7–18 months
post-diagnosis, results showed a significant interaction effect as the Met/Met genotype moder-
ated the relation between goal disturbance 7 months post-diagnosis and CAR one year later.
Patients who scored high on goal disturbance and had the Met/Met genotype, had more flat-
tened levels of CAR than patients who were high on goal disturbance and had the Val/Met
genotype. No interaction effects were found in the relation between goal disturbance and DCS.
Table 1. Patients’ demographics.
Variable No. (%)
Age, yrs, mean (SD) 65.2 (10.7)
Female 30 (41.7)
With partner 60 (83.3)
Education
Low (primary school/LBO) 11 (15.3)
Medium (high school/MBO) 35 (48.6)
High (college/university) 26 (36.1)
Prognosis (TNM stage)
Stage I 17 (23.6)
Stage II 24 (32.3)
Stage III 24 (32.3)
Stage IV 5 (6.9)
Presence of stoma (yes) 16 (22.2)
Site of tumour (colon) 45 (62.5)





(n = 72) (percentages may not add up to 100% due to missing data).
doi:10.1371/journal.pone.0135708.t001
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Table 2. Data for goal disturbance, cortisol levels, CAR, DCS, and COMT over time (n = 72). Paired samples t-tests were used to test significant differ-
ences between time 2 and time 3, and ANOVA’s with COMT genotype as between-group factor to test significant differences in cortisol levels between
genotypes.
Variable M (SD) Time 1: M (SD) Time 2: M (SD) Time 3: t (p)
Within 1 month post- diagnosis 7 months post-diagnosis 18 months post-diagnosis
Goal disturbance 4.9 (2.5) 4.0 (2.7) 3.3 (2.5)
Cortisol samples (nmol/L) 9.9 (5.6) 9.1 (4.3) 1.51 (.13)
Val/Val 10.95 (6.45) 9.58 (3.07)
Val/Met 10.12 (6.41) 9.15 (5.59)
Met/Met 8.81 (3.39) 8.81 (3.26)
F (p) .71 (.5) .13 (.88)
CAR .38 (.53) .28 (.61) 1.23 (.22)
Val/Val .25 (.32) .09 (.48)
Val/Met .45 (.53) .30 (.70)
Met/Met .32 (.64) .35 (.53)
F (p) .90 (.41) 1.0 (.37)
DCS -.16 (.06) -.15 (.05) -1.34 (.18)
Val/Val -.17 (.5) -.14 (.05)
Val/Met -.18 (.06) -.15 (.06)
Met/Met -.12 (.06) -.15 (.04)
F (p) 7.93 (<.001) .33 (.72)
doi:10.1371/journal.pone.0135708.t002
Table 3. Hierarchical regression analyses predicting cortisol 7 months post-diagnosis (Time 2).
Step 1 Step 2 Step 3 Step 4
B (SE) Beta B (SE) Beta B (Se) Beta B (Se) Beta
CAR Time 2
Age -.01 (.01) -.03 .00 (.01) .01 .00 (.01) .02 .00 (.01) .02
Gender -.02 (.13) -.02 -.04 (.13) -.04 -.07 (.13) -.07 -.06 (.14) -.06
Goal disturbance Time 1 - .03 (.03) .13 .03 (.03) .15 .03 (.04) .15
Val/Val - - -.24 (.17) -.19 -.21 (.17) -.17
Met/Met - - -.13 (.15) -.12 -.12 (.15) -.11
Goal disturbance × Val/Val - - - -.03 (.08) -.07
Goal disturbance × Met/Met - - - .02 (.06) .04
ΔR2 .00 .02 .03 .01 (total = .05)
DCS Time 2
Age .00 (.00) .07 .00 (.00) .10 .00 (.00) .08 .00 (.00) .06
Gender .02 (.02) .19 .02 (.02) .18 .03 (.01) .21 .03 (.02) .22
Goal disturbance Time1 - .00 (.00) .10 .00 (.00) .12 .00 (.00) .03
Val/Val - - .01 (.02) .08 .01 (.02) .08
Met/Met - - .07 (.02) .49** .07 (.02) .50**
Goal disturbance × Val/Val - - - .00 (.01) .04
Goal disturbance × Met/Met - - - .01 (.01) .11
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No interaction analyses were performed using only the 2-day CAR group, as group sizes would
be too small.
Discussion
The aim of the current study was to investigate the relation between goal disturbance and corti-
sol levels over time, and the moderating role of COMT herein. No significant relations were
found during the first six months after cancer diagnosis. During the year thereafter however,
we found indications that higher goal disturbance seven months post-diagnosis predicted
steeper or increased CAR the year thereafter. The direction of this finding was in line with our
hypothesis. No significant results were found with respect to the DCS. Additionally, in line
with our hypothesis, moderator analyses showed that patients who indicated to have a high
level of goal disturbance 7 months post-diagnosis were found to have more flattened CAR one
year later if they had the slow-activity COMT genotype Met/Met. No other significant interac-
tions were found.
The findings of the present study are the first to suggest a possible influence of goal distur-
bance after cancer on a physiological outcome (i.e. cortisol as a measure of response to stress).
Although studies that examined the effect of perceived stress on CAR found mixed results, the
evidence for an association between an increased CAR and chronic stress is growing and
becoming more robust [22,50]. The current results support the assumption that disturbance of
personally important life goals due to cancer can be considered a chronic stressor which affects
physiological aspects as the CAR. This is in line with the finding that the significant predictive
value of goal disturbance on CAR was only found between 7–18 months post-diagnosis, and
not during the first months after diagnosis. Only after several months of living with goal
Table 4. Hierarchical regression analyses predicting cortisol 18 months post-diagnosis (Time 3).
Step 1 Step 2 Step 3 Step 4
B (SE) Beta B (Se) Beta B (Se) Beta B(Se) Beta
CAR Time 3
Age -.01(.01) -.18 -.01 (.01) -.18 -.01 (.01) -.17 -.01 (.01) -.17
Gender .11 (.15) .09 .11 (.15) .09 .10 (.15) .08 .06 (.14) .05
Goal disturbance Time 2 - .01 (.03) .03 .01 (.03) .02 .09 (.04) .39*
Val/Val - - -.19 (.19) -.13 -.20 (.18) -.14
Met/Met - - .07 (.17) .06 .06 (.16) .05
Goal disturbance × Val/Val - - - -.08 (.07) -.16
Goal disturbance × Met/Met - - - -.18 (.06) -.48**
ΔR2 .04 .00 .03 .12 (total = .19)
DCS Time 3
Age .00 (.00) -.08 .00 (.00) -.11 -.00 (.00) -.11 .00 (.00) -.11
Gender .01 (.01) .06 .01 (01) .08 .01 (.01) .10 .01 (.01) .10
Goal disturbance Time2 - -.00 (.00) -.18 -.00 (.00) -.18 -.00 (.00) -.08
Val/Val - - .01 (.02) .10 .01 (.02) .09
Met/Met - - -.00 (.01) -.03 -.00 (.02) -.03
Goal disturbance × Val/Val - - - -.01 (.01) -.13
Goal disturbance × Met/Met - - - -.00 (.01) -.07
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disturbance, the stress may become chronic and the physiological effects visible. Chronic
stressors may require that people need to restructure their lives [11], and need to live with
ongoing challenging circumstances [18,55]. During the follow-up period, cancer patients may
need to do exactly that, and face daily goal disturbance caused by the illness. Anticipation of
these daily demands is also suggested to lead to an increased CAR [50].
No significant relation was found with respect to the DCS. As it is suggested that DCS may
reflect different processes than CAR [56,57], it could be that psychological stressors less affect
DCS. Given the responsiveness of CAR to psychological aspects, this measure is recommended
for studying the relation between psychological stressors, such as goal disturbance, and biologi-
cal responses [49]. More research is needed to examine which stressors may impact DCS.
Little is known about the role of the COMT genotype in the relation between stressors and
CAR and DCS. The present study found that, in line with our hypothesis, carrying the Met/
Met genotype led to a more flattened CAR over time when patients experienced more goal dis-
turbance. These results are the first to suggest a role of DNA genotype in CAR after goal distur-
bance in cancer patients. They indicate that Met/Met carriers, compared to the other COMT
variant carriers, may indeed have a relative insensitivity to modulating the endocrine stress
reactivity, and a reduced capability to degrade cortisol secretion [30]. Previous research sug-
gests that Met/Met carriers show inflexibility with adapting to changing situations and respond
more inefficiently to worries with respect to their cortisol levels [28,58,59]. It could be sug-
gested that only well after diagnosis, when permanent life changes are visible, the effect of
COMT genotype becomes visible. However, it should be further investigated why this effect
was only present in CAR 18 months post-diagnosis. Alternatively, Met/Met carriers might be
unable to exhibit the required physiological stress response due to their low reactivity. There-
fore, they may deal with goal disturbance more poorly overall and are more stressed.
The relationship between chronic stressors and adverse health effects is well established [18],
and cortisol may affect psychological [60] as well as physical well-being [20]. For cancer patients,
it seems especially important to maintain normative cortisol levels, as increased cortisol levels
have been related to a reduced immune function, which may promote tumor growth [11,23],
and prolonged cortisol secretion may lead to an increased risk for mortality in cancer patients
[11,23]. The relationship between CAR and health effects is less well established [49], but there is
evidence linking an increased CAR to several negative psychological and physical health out-
comes [50,61,62]. If increased CAR is indeed related to negative health outcomes, it is especially
important that cancer patients maintain a normative CAR and that goal disturbance is reduced.
Overall, studies found that carrying the Met/Met variant poses a risk factor for negative
emotional and physiological outcomes [28,31], and that Val/Val carriers are more resilient to
stress [28,58,59]. However, it remains difficult to say whether the Met/Met variant is detrimen-
tal for health when investigating CAR. Although flattened CARs are overall related to better
health outcomes, prolonged high cortisol levels may have adverse implications [11,23]. How-
ever, we did not find that patients in our sample with the Met/Met genotype had higher mean
levels of cortisol. More research is needed to examine the effect of COMT on CAR and the
implications for health. Yet, due to the influence of COMT on CAR, it could be relevant to
investigate whether patients experiencing goal disturbance have a specific COMT variant.
These patients may react differently to goal disturbance and form a risk group for adverse cor-
tisol levels. They should be monitored whether they may need extra care.
An additional finding was the significant relationship with the Met/Met COMT variant and
DCS 7 months post-diagnosis. Closer inspection of the data showed that patients with the Met/
Met variant had a more flattened DCS than patients with the Val/Val and Val/Met variants.
This finding is in line with our hypothesis and supports the assumption that Met/Met carriers
may be more insensitive to the endocrine reaction of the brain on stress and less able to degrade
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cortisol levels. Previous studies found that flattened DCS were linked to earlier mortality in can-
cer patients [23,26]. If indeedMet/Met carriers have more flattened DCS during the first months
post-diagnosis, it could be that COMT variant is a risk factor in cancer patients. Although these
suggestions are preliminary, this is a potentially interesting finding worth exploring in the future.
The present study has several strengths. First, we investigated the influence of goal distur-
bance on cortisol to gain information on the association with physiological functioning.
Hereby, we complement research using self-reported health, making a step in understanding
the relation between physiological and psychological processes in cancer patients. Also, we pre-
dicted two measures of cortisol (CAR and DCS), to assess the influence of goal disturbance on
different diurnal cortisol responses. Further, we averaged CAR and DCS from two consecutive
days, making it a more robust outcome measure. Lastly, we assessed cortisol longitudinally: 7
and 18 months post-diagnosis. Therefore we were able to investigate the long-term effect of
goal disturbance on cortisol. Some limitations merit attention. First, the sample size was rather
small, as we reduced the sample to eliminate possible contaminating sources to make the
results as reliable as possible. While the sample remained comparable to the original sample,
reducing the sample could have led to less power for the analyses. Second, due to the number
of statistical tests, there could be a chance of an inflated Type I error. However, considering the
novelty of the research topic, statistically correcting for multiple comparisons may be unneces-
sarily conservative. Third, we used the common method of calculating a difference score to
assess CAR, without taking the awakening sample as a reference value as has sometimes been
suggested (47). While both measures are possible, this may still have influenced the results.
Lastly, the use of certain medications could have an influence on HPA-axis functioning [63],
and smoking could have influenced cortisol levels [49]. We did not control for these factors
and this could have affected the results.
We have found the first suggestions of the effect of goal disturbance in cancer patients on
cortisol levels. Future research could further explore pathways with other biological indicators of
well-being as well. Additionally, it could be interesting to investigate whether these findings are
restricted to goal disturbance in cancer patients or can be found in patients with other (chronic)
illnesses as well. The potential health risks of adverse cortisol levels due to goal disturbance high-
lights the need to study how cancer patients can adjust their goals and maintain better physical
well-being. Additionally, as previous studies have shown that polymorphisms in other genes (e.g.
DAT andMAO-A) also modulate stress responses [30,31], including these in the analysis could
give further insight in the interaction between genes and stress responses [30,31].
In conclusion, the present study is the first to show that goal disturbance after cancer diag-
nosis may lead to increased cortisol awakening responses on the long term, but that this effect
is less pronounced for patients with the Met/Met COMT genotype. Future studies are needed
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